1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

$Thumbnail for Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Waterless Empirical Taste Test (WETT) and Patient Reported Outcomes (PRO) Data From TALisman$

MM - 793

Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Waterless Empirical Taste Test (WETT) and Patient Reported Outcomes (PRO) Data From TALisman

Nolan Ngo

Poster Presenter: Nolan Ngo

$Thumbnail for Treatment-Limiting On-Target Toxicity With Talquetamab/GPRC5D-Directed Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis$

MM - 795

Treatment-Limiting On-Target Toxicity With Talquetamab/GPRC5D-Directed Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz

SOHO 2026 Annual Meeting

Posters by Session

Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Waterless Empirical Taste Test (WETT) and Patient Reported Outcomes (PRO) Data From TALisman

Treatment-Limiting On-Target Toxicity With Talquetamab/GPRC5D-Directed Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Correlation Between Mobilization Regimen and CD34? Stem Cell Yield in Multiple Myeloma (MM) Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT): A Single-Center Retrospective Analysis

Generalizability Gaps in BCMA- and GPRC5D-Directed Immunotherapy Trials for Relapsed/Refractory Multiple Myeloma: A Trial-Level Eligibility Analysis

Temporal Trends and Demographic Disparities in Mortality From Multiple Myeloma and Leukemia With Coexisting Coagulation and Hemorrhagic Disorders in the United States, 1999-2024: A CDC WONDER Multiple-Cause Mortality Analysis

Racial Differences in Risk and Latency of Secondary Hematologic Malignancies Following Multiple Myeloma

National Trends in Pneumonia-Related Admissions Among Patients With Multiple Myeloma

GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH SIGNIFICANTLY REDUCED ALL-CAUSE MORTALITY, HOSPITALIZATION, AND SEPSIS IN PATIENTS WITH MULTIPLE MYELOMA AND TYPE 2 DIABETES: A PROPENSITY-MATCHED ANALYSIS OF THE TRINETX GLOBAL COLLABORATIVE NETWORK.

Transformation of Multiple Myeloma Survival in the Novel Therapy Era: From a Once Rapidly Fatal Disease to a Chronic Malignancy